The appearance of effects in vitro that do not appear in vivo is unfortunately extremely common.
One potential problem with ivermectin is it's patent expired in 1996. So not a lot of money to be made from a generic treatment that is cheap and abundant.
How far would Big Pharma go to secure profits? [2] Find out for yourself. Warning ignorance really is bliss and your worldview may be shaken.
[0] https://pubmed.ncbi.nlm.nih.gov/33592050/
[1] https://pubmed.ncbi.nlm.nih.gov/34466270/
[2] https://www.amazon.com/Real-Anthony-Fauci-Democracy-Children...
There are lots. And lots showing the opposite. Meta-analysis of those has shown that there are two factors with strong positively correlation with a study showing positive results for ivermectin:
(1) indicators of quality problems with the study, and
(2) the study being conducted where parasite infections known to exacerbate COVID and know to be treatable with ivermectin are endemic.
Ivermectin is a very good treatment for certain parasitic infections that make COVID worse, but there is very little reason to believe it is a good treatment for COVID aside from that. Which makes potentially it still a good component of treatment where undiagnosed parasitic infection is likely, but not more generally.
Testing a drug that is meant to act at a specific target to elicit response is a little different when considering in vitro studies. Usually there will be some tissue sample, such as lung tissue, which is infected with a virus. These infected samples are then tested with varying concentrations of the drug in question, but what makes the usual difference when moving to in vivo is primarily Absorption, Distribution, Metabolism, and Excretion (ADME). This changes how much of the drug and in what form gets to the target tissue, for example it could be run through first pass metabolism which may add or remove functional groups or break the compound down in some other way. This can change how much drug reaches the target, on top of the usual distribution mechanics that may prevent the drug from reaching some tissues at all.
Immunology isn't quite my field, so my understanding of the mechanics there are a bit lacking. The immune system is quite a bit different mechanically than drug distribution.
Sure, the antibody reactivity tests are first because those tests are fast. But a ton of the subsequent research focused on observational studies to quantify relative hospitalization risk.
Ivermectin, on the other hand, has no established mechanism which would make us expect it to work. It’s not impossible but given how only dodgy studies have shown beneficial effects by now it’d be a pretty big surprise to see benefits.
Kowa Co., Ltd. (hereinafter referred to as "Kowa") is the investigational drug "Ivermectin" used in Phase III clinical trials (development code: K-237) for the treatment of new coronavirus (SARS-CoV-2) infections. From a joint research (non-clinical trial) with Kitasato University, it was confirmed that the Omicron strain has the same antiviral effect as the existing mutant strain (alpha beta gamma delta strain). I did. As announced in July 2021, Kowa directly from Professor Satoshi Omura, a special honorary professor at Kitasato University, who won the Nobel Prize in Physiology or Medicine, about conducting clinical trials of ivermectin as a therapeutic drug for new coronavirus infections. I received a request. New Co. He believes that it is the mission of the pharmaceutical company to contribute to the treatment of coronavirus infections and protect the health of the people, and clinical trials to confirm the efficacy and safety of ivermectin against new coronavirus infections. We are conducting a test. Ivermectin has been distributed by WHO to infected areas for over 30 years as a treatment for parasitic infections. Especially in some African countries, it has been confirmed to be safe enough for volunteers to distribute directly to people. In addition, ivermectin has been reported to have the effects of suppressing the invasion of SARS-CoV-2 into cells and inhibiting replication, and is expected to be applied as a therapeutic drug (tablet) for new coronavirus infections as drug repositioning. I am. In this clinical trial, the dosage and administration are different from those already approved for the treatment of parasitic infections, but the efficacy and safety are being confirmed in the clinical trial. Kowa will contribute to the treatment of new coronavirus infections by confirming the clinical effect of ivermectin on SARS-CoV-2 and providing it to the public as soon as possible. * Overseas, it was reported that patients use high-content ivermectin for animals, which is dangerous to humans, and harmful events occur. Kowa is the standard for conducting clinical trials of pharmaceuticals in humans. Ivermectin clinical trials are conducted in accordance with the strict standards set by GCP (Good Clinical Practice).
From that I believe it's this trial: https://clinicaltrials.gov/ct2/show/NCT05056883
Double blind, 1000 participants (all mild COVID), small standard human does. The outcome variable is basically how the patient feels (improvement of clinical symptoms).